"Not So Different": What Did the First Half of 2019 Hold for Biosimilars?

July 21, 2019

At the beginning of this year, we spoke with Laura Joszt, associate editorial director and the host of The American Journal of Managed Care’s podcast, Managed Care Cast, about where biosimilars stood at the end of 2018. Now, halfway through the year, we’re continuing that conversation with a look at how biosimilars have fared so far in 2019.

At the beginning of this year, we spoke with Laura Joszt, associate editorial director and the host of The American Journal of Managed Care’s podcast, Managed Care Cast, about where biosimilars stood at the end of 2018. Now, halfway through the year, we’re continuing that conversation with a look at how biosimilars have fared so far in 2019.

Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States. Learn more here.

Hear our discussion about pay-for-delay settlements, read an expert perspective on the FDA’s guidance on interchangeability, or see a visual representation of the US- and EU-approved biosimilars.

Related Content:

Podcasts | Regulatory | Business

x